Skip to main content
. Author manuscript; available in PMC: 2010 Dec 3.
Published in final edited form as: Oncogene. 2010 Apr 12;29(22):3208–3216. doi: 10.1038/onc.2010.103

Figure 4. Dasatinib inhibits EGF-induced AR phosphorylation at Tyr-534 but not Tyr-267.

Figure 4

(A) LNCaP cells were pre-treated with dasatinib (10 nM) for 2 hours, then treated with EGF (100 ng/ml) for 60 or 90 min. Protein extracts were immunoprecipitated with the AR antibody, then immunoblotted with the antibody specific for phospho-Y534 AR or total AR. (B) LNCaP cells were pre-treated with dasatinib at increasing concentrations for 2 hours, then treated with EGF (100 ng/ml) for 60 min. Protein extracts were immunoblotted with the antibody against phospho-Y267 AR or total AR. (C, D) LNCaP cells were treated as above. Cells were also treated with heregulin (10 ng/ml) for 60 min as a positive control of Ack1 activation. Protein extracts were immunoblotted with the antibody against phospho-Ack1 or total Ack1 or phospho-Src or total Src. Blots shown are representative of three independent experiments.